Navigation Links
ProImmune Launches New MHC-Peptide Binding Assay for Class II HLA Alleles

OXFORD, England, September 24 /PRNewswire/ -- ProImmune Ltd., a leading provider of quality research reagents for monitoring the immune system and services for antigen discovery, has announced the launch of its new MHC-peptide binding assay for Class II HLA alleles, adding to the series of discovery services for Class I HLA already available from the Company.

The Class II REVEAL(TM) binding assay for HLA alleles DR1-4, is a powerful cell-free in vitro assay that can rapidly predict T-cell antigens in any protein sequence. It is widely applicable across many disease areas such as cancer, infectious diseases, autoimmunity and in transplantation, and is ideally suited to therapeutic programmes with time pressures, such as the development of vaccines for emerging diseases.

Unlike traditional methods for discovering T-cell antigens, such as functional cellular assays, the Class II REVEAL(TM) assay does not use patient samples, and uniquely determines the HLA restriction of each antigen in a single step. Class II REVEAL(TM) therefore offers a significant timesaving advantage, and reduces the overall cost and risk of discovery projects.

The launch of Class II REVEAL(TM) follows ProImmune's recent extension of its range of MHC Class II Ultimer(TM) staining reagents with alleles DR2 and DR3 to cover HLA DR1 to 4. Class II Ultimers(TM) can be used to validate antigens discovered with REVEAL(TM), and in monitoring and phenotyping of targeted immune responses.

Dr. Nikolai Schwabe, CEO of ProImmune, said "Class II REVEAL(TM) helps to overcome a significant barrier in understanding key helper T-cell immune responses in detail, and to harness such responses in the design of highly targeted therapies across a very wide range of diseases".

ProImmune Ltd is a private biotechnology company based in Oxford, UK, that specializes in providing antigen discovery services and research reagents for monitoring the immune system. ProImmune has a wide range of customers from pharmaceutical and biotechnology companies, to clinical and academic research institutes throughout the world. The Company, founded in November 1999, has secured R&D funding from several DTI Smart, EUREKA and EU Framework VI project grants and has been profitable since its inception. ProImmune owns a portfolio of international patents and patent applications protecting its core products and technologies. The Company also has offices in the USA.

Media enquiries:

Gemma Price

Northbank Communications

Tel: +44-(0)-20-7268-3002


SOURCE ProImmune Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Merge launches diagnostic mammography workstation in Europe
2. Einstein Wireless launches cellular alert system
3. Logistics Health launches compliance management tool
4. UW-Madison launches new high-speed research network
5. UWM launches research foundation
6. TeraMedica launches information manager
7. GE Healthcare launches hybrid electronic record
8. Cedara launches new version of DICOM toolkit
9. Merge launches Spanish version of imaging tool
10. Doyle launches 2025 alternative energy plan
11. Jellyfish launches comparative shopping website
Post Your Comments:
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
Breaking Biology Technology:
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):